---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218192"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2026-05-12T11:33:15+00:00"
generated_at: "2026-05-12T11:36:36.839264+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma Q1 2026 net loss $6.7M; setrusumab regulatory dialogue initiated for pediatric OI

## Summary
- Net loss $6.7M vs $12.9M YoY; cash $36.2M as of March 31, expected runway into mid-2027.
- Setrusumab Phase 3 studies missed primary fracture endpoint but achieved significant bone mineral density and PRO improvements; regulatory engagement for pediatric OI started.
- Alvelestat partnership discussions ongoing; single Phase 3 trial (~220 patients) could start within 6 months of deal.
- Vantictumab Phase 2 in osteopetrosis expected H2 2026 by partner āshibio; Mereo retains European rights.
- R&D expenses $4.7M (+$0.8M YoY) driven by setrusumab manufacturing costs; G&A $4.0M (-$3.3M) due to ADR reimbursement and savings.

## SEC filing metadata
- accession: 0001193125-26-218192
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2026-05-12T11:33:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/0001193125-26-218192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/mreo-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218192
- JSON: https://secwatch.observer/filing/0001193125-26-218192.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218192.txt

## Key facts
- Earnings Releases
  Mereo BioPharma Group plc reported the first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $6.7 million.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss for the first quarter of 2026 was $6.7 million
  - Result: reported results
  source text: On May 12, 2026, Mereo BioPharma Group plc announced its financial results for the first quarter ended March 31, 2026 and provided an update on recent corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312526218192/0001193125-26-218192-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.